FIGURE

Figure 3

ID

ZDB-FIG-221214-130

Publication

Poudel et al., 2022 - Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation

Other Figures

All Figure Page

Back to All Figure Page

Figure 3

Inhibition of doxorubicin-induced osteoclast differentiation by resveratrol. RAW 264.7 cells were cultured for 4 days with M-CSF (30 ng/mL) and RANKL (50 ng/mL) and treated with resveratrol (RES) and doxorubicin (DOX) alone or combined. Levels of mRNA expression for Oc-stamp (A), Rank (B) Trap (C), Ctsk (D), Nfatc1 (E) and Nf-kb p105 (F) were analyzed by qPCR. One-way ANOVA, Tukey’s multiple comparisons test, *—p ≤ 0.05, **—p ≤ 0.01, ***—p ≤ 0.001, ****—p ≤ 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Mol. Sci.